What is Torsades de Pointes?
Torsades de pointes (TdP) is a life-threatening polymorphic ventricular tachycardia characterized by twisting QRS complexes around the isoelectric baseline that occurs in the setting of QT interval prolongation and can rapidly degenerate into ventricular fibrillation and sudden cardiac death 1, 2.
Key Defining Features
TdP has three essential characteristics that distinguish it from other ventricular arrhythmias:
- Polymorphic QRS morphology with a characteristic "twisting of the points" appearance where the QRS axis undulates around the baseline 3, 4
- Prolonged QT interval (typically QTc >500 ms or increase of ≥60 ms from baseline) 3
- Self-terminating episodes that can recur or progress to ventricular fibrillation 5
Underlying Mechanisms
The arrhythmia is initiated by triggered activity from early afterdepolarizations (EADs) and maintained by reentry within a substrate of inhomogeneous myocardial repolarization 4. Recent research demonstrates that spontaneous termination occurs when there is sudden homogenization of myocardial repolarization with recovery of normal action potential configuration 5.
Common Precipitating Factors
TdP occurs in two clinical contexts:
Acquired Long QT Syndrome (most common in hospital settings):
- QT-prolonging medications (antiarrhythmics, antibiotics, antipsychotics, antiemetics)
- Electrolyte disturbances: hypokalemia, hypomagnesemia, hypocalcemia 2, 6
- Bradycardia or pauses 7
- Drug-drug interactions 3
Congenital Long QT Syndrome 8
Critical Clinical Pitfall
TdP is frequently misdiagnosed as benign non-sustained ventricular tachycardia (NSVT), which can lead to dangerous management errors 2. The key distinguishing feature is the presence of QT prolongation—always measure the QT interval when evaluating any polymorphic ventricular tachycardia.
Immediate Management Priorities
When TdP is identified, the guideline-recommended actions are 3:
- Immediate DC cardioversion if the arrhythmia does not self-terminate or degenerates into ventricular fibrillation
- Intravenous magnesium sulfate 2 g as first-line pharmacologic therapy, regardless of serum magnesium level (Class IIa recommendation)
- Remove the offending agent in drug-induced cases (Class I recommendation)
- Correct electrolyte abnormalities (potassium, magnesium, calcium)
- Increase heart rate to prevent pauses that trigger TdP (temporary pacing if needed)
Monitoring Requirements in Hospital Settings
For patients receiving QT-prolonging drugs, the protocol should include 3:
- Baseline QTc measurement before drug initiation
- Serial QTc monitoring every 8-12 hours after starting or increasing dose
- More frequent monitoring if QTc exceeds 500 ms or increases ≥60 ms from baseline
- Continuous cardiac monitoring for highest-risk drugs with immediate defibrillator availability
- Do not transport patients from monitored units when QTc is critically prolonged with ECG signs of impending TdP
The duration of monitoring depends on drug half-life and elimination time—for example, ibutilide-induced TdP occurs within 1 hour of infusion end, so monitoring beyond 3 hours is unnecessary 3.